ALDX Up as FDA Accepts Resubmitted NDA for Eye Drug Reproxalap [Yahoo! Finance]
Aldeyra Therapeutics Announces FDA Acceptance for Review of Reproxalap New Drug Application for the Treatment of Dry Eye Disease, Expands AbbVie Option Agreement
Aldeyra Therapeutics to Participate in the Jefferies London Healthcare Conference
Aldeyra Therapeutics Selected to Present at the Disruptive Innovations Symposium during the OSN New York Retina 2024 Meeting
Aldeyra Therapeutics resubmits new drug application for treatment of dry eye disease [Seeking Alpha]